2025
November 2025
Aura Biosciences is leveraging a novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications with an initial focus on ocular and urologic oncology.
September 2025
The team at Profound Therapeutics is making profound impacts on their understanding of biology and disease, empowering them to create therapeutics that would not have previously been possible – another step closer to making a profound impact on human health.
September 2025
Adverum is driven to establish gene therapy as a new standard of care for the leading causes of vision loss.
2024
December 2024
Prime Medicine™ was founded with a goal of transforming the lives of patients with debilitating diseases through the application of our groundbreaking Prime Editing platform and technology.
August 2024
Ohalo’s breakthrough technology, Boosted Breeding, will usher in a new era of improved agricultural productivity to radically transform global agriculture.
July 2024
Arena BioWorks is focused on human biology, with a mission to understand mechanisms of disease in the context of human physiology and to translate those insights into new medicines that impact human health.
May 2024
Jasper is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases.
March 2024
C4 Therapeutics is dedicated to delivering on the promise of targeted protein degradation (TPD) to create a new generation of medicines that transforms patients’ lives.
January 2024
Karuna is a biopharmaceutical company driven to discover, develop and deliver transformative medicines for people living with psychiatric and neurological conditions.
2023
August 2023
Protego Biopharma focuses on the discovery and development of first- or best-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various systemic amyloid diseases, such as light chain (LC) amyloidosis.
August 2023
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.
2022
September 2022
With offices in Cambridge and London, UK, Sosei Heptares is focused on the discovery and early development of new medicines originating from their proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities.
May 2022
With offices in Cambridge, MA, San Francisco, CA and Zug Switzerland CRISPR Therapeutics is focused on developing transformative gene-based medicines for serious human diseases.
April 2022
Located in Watertown, MA, Disc Medicines is committed to building a brighter future for patients. Using new discoveries and insights in hematology, they are advancing the frontiers of biology to create life-changing medicines.
March 2022
Located in Boston, MA, Ensoma is expanding the boundaries of genetic medicine – from rare monogenic illnesses to prevalent polygenic conditions such as autoimmune disease and cancer that affect millions around the world.
2021
May 2021
Headquartered in Philadelphia, PA Spark Therapeutics, is committed to discovering, developing and delivering gene therapies to address genetic diseases including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.
March 2021
Headquartered in Cambridge, MA, KSQ is a preclinical-stage biotech that has rapidly advanced the field of CRISPR-enabled functional genomics, from in vitro cell autonomous screens to more complex genome-scale screens of immune cells in vivo.
February 2021
Headquartered in Hayward, CA, Arcus was founded with the vision of bringing together scientists, physicians, advisors, and other leaders with significant content-matter expertise to focus on developing highly-combinable, best-in-class cancer therapies.
2020
November 2020 – Headquartered in Cambridge, MA Seres Therapeutics is a late-clinical stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.
October 2020 — Headquartered in South San Francisco, CA, Atreca focuses on the immune response of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies, including those in our lead programs in Oncology.
October 2020 — With offices in Waltham, MA, Adagio's mission is to provide an effective long-term solution for the global Coronavirus challenge.
September 2020 — Located in Austin, TX, Molecular Templates is focused on the discovery, development and commercialization of next generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancer.
August 2020 — With offices in Cambridge, MA, Celsius' mission is to develop life-saving medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.
February 2020 — With offices in Cambridge, MA, Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
January 2020 — With US offices in San Diego and South San Francisco, Shouti Pharmaceuticals will be using R&D Logic's R&D Time to manage and prioritize portfolio resources.
June 2021
Based in San Francisco and Boston, Foresite Labs partners broadly to launch life sciences and healthcare companies that use the tools of data science to solve our greatest unmet medical needs.